NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices | MicrobiomeTrials← Back to trialsNCT07806149
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-10-28Est. Completion: 2029-03-01
Enrollment target: 200 participants Locations- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Emory University Hospital, Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- St. Francis Hospital & Heart Center, Roslyn, New York, United States
- Montefiore Medical Center: Einstein Campus, The Bronx, New York, United States
- WellSpan York Hospital, York, Pennsylvania, United States
- Univ. of Virginia, Charlottesville, Virginia, United States
- Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States
Other microbiome trials you might be interested in
Syndromic and Metabolic CardiomyopathyCardiomyopathies
The goal of this cohort study is to investigate the clinical characteristics of SMCs and to explore the difference in ca…
Beijing, ChinaCompleted Jul 20, 2026
Non-obstructive Hypertrophic Cardiomyopathy
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess…
La Jolla, United StatesEst. completion Dec 2026